


Amendments to the Claims

Please amend the claims to read as follows:

Claims 1-60 (Cancelled).

Claim 61 (New): A compound of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein:

R^1 is H, alkyl, haloC₁-C₆ alkyl, cycloalkyl, cycloalkylNH-, arylalkyl, heterocycloalkyl, heteroaryl, N(R²)₂, or NR²aryl, unsubstituted aryl or aryl substituted with one to three X;

R^2 is the same or different in each occurrence and is independently selected from H or C₁-C₆ alkyl;

R^3 is H, C₁-C₆ alkyl, Cl, F, CF₃, OCF₂H, OCF₃, OH or C₁-C₆ alkoxy;

R^4 is H, C₁-C₆ alkyl, C₁-C₆ alkoxy, cycloalkyl, alkenyl, aryl, benzyl, arylNH-, cycloalkylNH-, N(R²)₂, or NR²aryl, said alkyl, alkoxy, cycloalkyl, alkenyl, or aryl optionally substituted with one to three X;

R^5 is H or C₁-C₆ alkyl;


R^6 is H or C₁-C₆ alkyl; or


R^5 and R^6 taken together with the carbon atom form a carbonyl group;

L^1 is -S(O₂)-, -S(O)-, or -S-;

L^2 is -S(O₂)-, -S(O)-, or -S-;

X is the same or different, and is independently selected from H, halogen, CF_3 , CN, OCF_2H , OCF_2CF_3 , OCF_3 , OR^2 , $\text{C}_1\text{-C}_6$ alkyl, cycloalkyl, cycloalkoxy, $\text{C}_1\text{-C}_6$ alkoxy, alkoxy $\text{C}_1\text{-C}_6$ alkoxy, O-cycloalkyl, cycloalkylamino, cycloalkylalkoxy, heteroalkyl, $-\text{OSO}_2\text{R}^2$, $-\text{COOR}^2$, $-\text{CON}(\text{R}^2)_2$, NHR^2 , arylNH- , $\text{N}(\text{R}^2)_2$, or NR^2 aryl;

Y is a covalent bond, $-\text{CH}_2-$, $-\text{S}(\text{O}_2)-$, or ;

Z is a covalent bond, $-\text{CH}_2-$, $-\text{S}(\text{O}_2)-$ or ; or

Y, R^1 , Z and R^2 can be taken together with the nitrogen atom to form a heterocycloalkyl; with the proviso that if Y is a covalent bond, R^1 cannot form a N-N bond with the nitrogen atom; and

n is an integer of 0 to 4.

Claim 62 (New): A compound according to claim 61 wherein

L^1 is $-\text{SO}_2-$, $-\text{S-}$ or $-\text{S}(\text{O})-$;

L^2 is $-\text{SO}_2-$;

R^1 is H, $\text{CH}_3\text{NH-}$, $-\text{CH}_2\text{CF}_3$, $-\text{NHC}_3\text{H}_7$, $-\text{NHC}_2\text{H}_5$, $-\text{NHC}_4\text{H}_9$, $\text{C}_1\text{-C}_6$ alkyl, $-\text{CF}_3$, $-\text{CH}(\text{CH}_3)_2$, thiophenyl, morpholinyl, cyclopropyl, cyclopentyl, benzyl, naphthyl,

$-\text{C}(\text{CH}_3)_3$, NHphenyl, 3,5-difluorophenyl, phenyl, N-cyclopentyl or $\text{N}(\text{CH}_3)_2$;


R^2 is H or $-\text{CH}_3$;

R^4 is $\text{C}_1\text{-C}_6$ alkoxyl, cyclohexyl, cyclopentyl, phenyl, tolyl, C_3H_7 , trifluoromethoxyphenyl, or $-\text{CH}_3$; and

each R^4 may be optionally substituted with one to three substituents, which are the same or different and are independently selected from X;

R^5 and R^6 are independently H or $-\text{CH}_3$;

X is H, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkoxy, halogen, $-\text{CF}_3$, $-\text{OCH}_3$, $-\text{OCF}_3$, $-\text{OCF}_2\text{H}$, $-\text{CH}_3$ or $\text{C}_1\text{-C}_6$ cycloalkyl;



Z is a covalent bond; or

R^1 , Y, R^2 and Z taken together with the nitrogen atom form a morpholinyl group.

Claim 63 (New): The compound according to claim 62 wherein

L^1 is $-\text{SO}_2-$ or $-\text{CH}_2-$;

L^2 is $-\text{SO}_2-$;


R^1 is $-\text{CH}_3$ or $-\text{CF}_3$; and

R^4 is phenyl, optionally substituted with one to three substituents which are the same or different, and are independently selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 alkoxy, OH, $-\text{CF}_3$ and halogen.

Claim 64 (New): The compound according to claim 63 wherein R^4 is phenyl substituted with $-\text{OCH}_3$ or halogen.











Claim 65 (New): The compound according to claim 64 wherein the halogen is selected from fluorine and chlorine.










Claim 66 (New): The compound according to Claim 61 of the formula















a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;

wherein X and R⁴ are as shown in the table below:


	X	R ⁴
A	-OCH ₃	
B	-OCH ₃	
C	-OCF ₂ H	
F	-OCH ₃	
G	-CH ₃	
I	-OCH ₃	
J	-OCF ₃	
L	Cl	
O	Cl	
Q	CH ₃	

	X	R ⁴
Z	-OCH ₃	
AA	-OCH ₃	C ₃ H ₇
AB	-CF ₃	
AC	-CF ₃	
AF	-CF ₃	
AI	-CF ₃	
AK	Cl	
AQ	Cl	
AU	Cl	
AX	Cl	C ₃ H ₇
BA	-OCF ₃	

	X	R ⁴
BB	-OCF ₃	
BC	-OCF ₃	
BG	-OCH ₃	
CB	-CH ₃	
CE	Cl	
CW	OH	
CX	OH	
DA	-OCF ₂ H	
FR	H	
FS	H	



	X	R ⁴
FT	H	
FW	H	










Claim 67 (New): The compound according to Claim 1 of the formula












a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;


wherein X and R⁴ are as shown in the table below:

	X	R ⁴
R	-CF ₃	
S	Cl	

W	Cl	
AE	-CF ₃	
AG	-CF ₃	
AH	-CF ₃	
AR	Cl	
AS	Cl	
BD	-OCF ₃	
BJ	-OCH ₃	
BZ	-CH ₃	

CA	-CH ₃	
FY	H	
FZ	H	
GI	Cl	
GJ	-OCH ₃	
GL	OH	
GM	OCH(CH ₃) ₂	
GN		














Claim 68 (New): The compound according to Claim 61 of the formula














a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;


wherein X, R¹ and R⁴ are as shown in the table below:

	X	R ¹	R ⁴
A	-OCH ₃	-CH ₃	
C	-OCF ₂ H	-CH ₃	
G	-CH ₃	-CH ₃	
L	Cl	-CH ₃	
R	-CF ₃	-CF ₃	
S	Cl	-CF ₃	

	X	R ¹	R ⁴
AB	-CF ₃	-CH ₃	
AT	Cl	-N(CH ₃) ₂	
BA	-OCF ₃	-CH ₃	
BD	-OCF ₃	-CF ₃	
BZ	-CH ₃	-CF ₃	
FS	H	-CH ₃	
FY	H	-CF ₃	
XXX		-CF ₃	
XXXII	-CN	-CF ₃	
XXXIII	-NH ₂	-CF ₃	
XXXIV		-CF ₃	


	X	R ¹	R ⁴
XXXIX	-CONH ₂	-CF ₃	
XXXX	-OCH ₃	-CF ₃	
XXXXI	-OH	-CF ₃	
XXXII		-CF ₃	
XXXIII		-CF ₃	
XXXIV		-CF ₃	
XXXXV		-CF ₃	

Claim 69 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{OCH}_3$ and R^1 is $-\text{CH}_3$.

Claim 70 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{OCF}_2\text{H}$ and R^1 is $-\text{CH}_3$.

Claim 71 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{CH}_3$ and R^1 is $-\text{CH}_3$.

Claim 72 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R¹ is -CH₃.

Claim 73 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -CF₃ and R¹ is -CF₃.

Claim 74 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R¹ is -CF₃.

Claim 75 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -CF₃ and R¹ is -CH₃.

Claim 76 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R¹ is -N(CH₃)₂.

Claim 77 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -OCF₃ and R¹ is -CH₃.

Claim 78 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -OCF₃ and R¹ is -CF₃.

Claim 79 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -CH₃ and R¹ is -CF₃.

Claim 80 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R¹ is -CH₃.

Claim 81 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R¹ is -CF₃.

Claim 82 (New): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R¹ is -CF₃.

Claim 83 (New): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R¹ is CH₃.

Claim 84 (New): A pharmaceutical composition comprising an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 61 and a pharmaceutically acceptable carrier.

Claim 85 (New): A pharmaceutical composition comprising an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 67 and a pharmaceutically acceptable carrier.

Claim 86 (New): A method of stimulating cannabinoid CB₂ receptors in a mammal comprising administering to a mammal having CB₂ receptors an effective CB₂ receptor stimulating amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to Claim 61.

Claim 87 (New): A method of treating cancer, inflammatory diseases, immunomodulatory diseases, or respiratory diseases comprising administering to a mammal in need of such treatment an effective amount of a compound, a

prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 61.

Claim 88 (New): A method of treating cutaneous T cell lymphoma, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, glaucoma, diabetes, sepsis, shock, sarcoidosis, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, retinal disease, scleroderma, osteoporosis, renal ischemia, myocardial infarction, cerebral stroke, cerebral ischemia, nephritis, hepatitis, glomerulonephritis, cryptogenic fibrosing alveolitis, psoriasis, atopic dermatitis, vasculitis, allergy, seasonal allergic rhinitis, Crohn's disease, inflammatory bowel disease, reversible airway obstruction, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, colitis, coronary artery disease, melanoma, transplant rejection, graft versus host disease, Hashimoto's thyroiditis, Graves disease, myasthenia gravis or Goodpasture's syndrome comprising administering to a mammal in need of such treatment an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 61.

Claim 89 (New): The method of claim 86 wherein the condition or disease treated is selected from rheumatoid arthritis, multiple sclerosis, seasonal allergic rhinitis and chronic obstructive pulmonary disease.

Claim 90 (New): A pharmaceutical composition made by combining the compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, of Claim 61 and a pharmaceutically acceptable carrier therefor.

Claim 91 (New): A process for making a pharmaceutical composition comprising combining a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, of Claim 61 and a pharmaceutically acceptable carrier.

Claim 92 (New): A method of treating rheumatoid arthritis which comprises co-administration of a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF- α compound or other classes of compounds indicated for the treatment of rheumatoid arthritis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, of Claim 61.

Claim 93 (New): A method of treating rheumatoid arthritis which comprises co-administration of a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF- α compound, a PDE IV inhibitor or other classes of compounds indicated for the treatment of rheumatoid arthritis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 67.

Claim 94 (New): The method of Claim 92 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is Enbrel or Remicade.

Claim 95 (New): The method of Claim 93 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is Enbrel or Remicade.

Claim 96 (New): A composition for treating rheumatoid arthritis which comprises a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF- α compound or other classes of compounds indicated for the treatment of rheumatoid arthritis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 61.

Claim 97 (New): A composition for treating rheumatoid arthritis which comprises a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF- α compound or other classes of compounds indicated for the treatment of rheumatoid arthritis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 67.

Claim 98 (New): The composition of Claim 96 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is Enbrel or Remicade.

Claim 99 (New): The composition of Claim 97 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is Enbrel or Remicade.

Claim 100 (New): A method of treating multiple sclerosis which comprises co-administration of a compound selected from Avonex, Betaseron, Copaxone or other compounds indicated for the treatment of multiple sclerosis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 61.

Claim 101 (New): A method of treating multiple sclerosis which comprises co-administration of a compound selected from Avonex, Betaseron, Copaxone or other compounds indicated for the treatment of multiple sclerosis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, of Claim 67.

Claim 102 (New): A composition for treating multiple sclerosis which comprises a compound selected from Avonex, Betaseron, Copaxone or other compounds indicated for the treatment of multiple sclerosis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, of Claim 61.

Claim 103 (New): A composition for treating multiple sclerosis which comprises a compound selected from Avonex, Betaseron, Copaxone or other compounds indicated for the treatment of multiple sclerosis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, of Claim 67.

Claim 104 (New): A method of treating psoriasis which comprises co-administration of a compound selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF- α compound or other classes of compounds indicated for the treatment of psoriasis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, of Claim 61.

Claim 105 (New): A method of treating psoriasis which comprises co-administration of a compound selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF- α compound or other classes of compounds indicated for the treatment of psoriasis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 7.

Claim 106 (New): The method of Claim 104 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is Enbrel or Remicade.

Claim 107 (New): The method of Claim 105 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is Enbrel or Remicade.


Claim 108 (New): A composition for treating psoriasis which comprises a compound selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF- α compound or other classes of compounds indicated for the treatment of psoriasis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 61.

Claim 109 (New): A composition for treating psoriasis which comprises a compound selected from the class consisting of an immunosuppressive, a steroid, an anti-TNF- α compound or other classes of compounds indicated for the treatment of psoriasis and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, as defined in Claim 67.

Claim 110 (New): The composition of Claim 108 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is Enbrel or Remicade.


Claim 111 (New): The composition of Claim 109 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β -methasone and the anti-TNF- α compound is Enbrel or Remicade.

Claim 112 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{OCH}_3$ and R^1 is $-\text{CH}_3$.

Claim 113 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{OCF}_2\text{H}$ and R^1 is $-\text{CH}_3$.

Claim 114 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{CH}_3$ and R^1 is $-\text{CH}_3$.

Claim 115 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R¹ is -CH₃.

Claim 116 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -CF₃ and R¹ is -CF₃.

Claim 117 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R¹ is -CF₃.

Claim 118 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -CF₃ and R¹ is -CH₃.

Claim 119 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R¹ is -N(CH₃)₂.

Claim 120 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -OCF₃ and R¹ is -CH₃.

Claim 121 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -OCF₃ and R¹ is -CF₃.

Claim 122 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -CH₃ and R¹ is -CF₃.

Claim 123 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R¹ is -CH₃.

Claim 124 (New): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R^1 is $-\text{CF}_3$.

Claim 125 (New): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is $-\text{CF}_3$.

Claim 126 (New): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is CH_3 .